Annexin Pharmaceuticals AB (publ) (FRA:Q910)

Market Cap	8.67M -52.5%
Revenue (ttm)	n/a
Net Income	-3.84M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.205
Previous Close	1.205
Day's Range	1.205 - 1.205
52-Week Range	1.025 - 2.640
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About FRA:Q910

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, ...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: Q910

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error